What are the indications for Entrectinib/Luo Shengquan?

Entrectinib (Entrectinib) is an innovative targeted therapy drug mainly used to treat advanced cancers related to specific gene mutations. As an oral small molecule tyrosine kinase inhibitor, entrectinib can specifically inhibit the neurotrophic tyrosine receptor kinase (NTRK) fusion gene, ROS1 gene mutation and other related molecular signaling pathways, thereby effectively inhibiting the growth and spread of tumors.

The main indications for entrectinib include:

1. NTRK fusion gene-positive solid tumors: Entrectinib is approved for the treatment of adult and pediatric patients 12 years of age and older who require a validated test method to confirm solid tumors carrying the NTRK fusion gene. NTRK gene fusion is associated with the occurrence of a series of cancers, including non-small cell lung cancer (NSCLC), soft tissue sarcoma, brain tumors, etc. The presence of NTRK fusion genes can cause uncontrolled proliferation of tumor cells, and entrectinib effectively inhibits tumor growth by inhibiting the transmission of these abnormal signals. Entrectinib offers a new treatment option for some patients with advanced cancer who do not respond well to traditional treatments.

2. ROS1-positive locally advanced or metastatic non-small cell lung cancer (NSCLC): Entrectinib is also approved for adult patients with positive ROS1 gene mutations. ROS1 gene mutations occur in a subset of patients with non-small cell lung cancer, and this mutation is closely related to the rapid proliferation and metastasis of cancer cells. Entrectinib can effectively inhibit tumor growth by specifically inhibiting the abnormal signaling of the ROS1 gene, providing a new treatment hope especially for patients who have failed other treatments.

Through these two main indications, entrectinib provides personalized treatment options in the field of cancer treatment. Compared with traditional chemotherapy drugs, entrectinib, as a targeted therapy drug, can act more precisely on the molecular mechanism of tumors and reduce damage to normal cells, thereby reducing side effects and improving treatment effects.

Reference materials:https://www.roche.com/products/rozlytrek